Deleted Tweets From Scott Gottlieb, R-D.C.

The FDA and industry have to accelerate the adoption of advanced and smart manufacturing technologies to strengthen the nation’s public health infrastructure. To this end, the FDA is creating a new collaboration with @NIST. #FDAVoices https://t.co/mfpGYpWDSt

So far at the IMFs in FY 2020 the FDA has screened and refused admission to more than 34,000 products with more than 24,000 being violative drug products that were destroyed.

As we continue to fight #COVID19, FDA remains steadfast in making real time decisions based on evolving information and science. This has been consistently applied throughout the pandemic in our approach to diagnostics, PPE and potential therapies.

RT @AnandShahFDA: Having fun in the sun? Practice social distancing, wear a mask, and wash your hands. Also check out @US_FDA's lates… https://t.co/oVc60hONiM

If you’ve had #COVID19, please help your family, friends, neighbors, and fellow Americans by donating plasma today QT @WhiteHouse: "We've seen that this is a safe treatment, and we're encouraged by the early, promising data that we've seen ... Th… https://t.co/qZf6btF8oT)

RT @Mike_Pence: Wheels up to Florida with @SteveFDA to visit @umiamimedicine to mark the beginning of Phase-3 clinical trials with… https://t.co/V9sreCjsiu

Submit your questions for our next session of #AskFDA. QT @US_FDA: Let’s do it again! Join @SteveFDA as he answers your questions about anything FDA. Send your questions using… https://t.co/zsaltoO3bK)

RT @DrAbernethyFDA: It was a pleasure to participate in The Next Era of Healthcare @BloombergLive discussion including the new use of t… https://t.co/Dld8mKzpgf

We are proud to participate in the COVID-19 Diagnostics Evidence Accelerator, a multi-stakeholder project organized by @reaganudall in collaboration with @CancerResearch.

RT @US_FDA: Throughout its history, FDA has warned Americans against buying fraudulent medical devices. Be a #cautiousconsumer… https://t.co/m1MQhHRhy0

FDA will continue to enhance & expand its work to accelerate novel #COVID19-related therapies & intends to provide additional information in the near future to give Americans a greater understanding of the full extent of our work in this area.

Convalescent plasma & hyperimmune globulin are blood products made from the blood of recovered #COVID19 patients. Because these products contain antibodies to the disease, they may help sick #coronavirus patients by shortening the length or lessening the severity of the illness.

As part of CTAP’s work, FDA is collaborating with government, industry & academic partners to facilitate the development & use of plasma & blood products for the potential treatment of #COVID19. https://t.co/JAjUEBSy6c

FDA has, among other things redeployed medical & regulatory staff to serve on review teams dedicated to #COVID19 therapies, streamlined processes & operations for developers & scientists to send inquiries & requests, & provided resources to health care providers & researchers.

Through CTAP, FDA is triaging requests from developers & scientists seeking to develop new drug & biologic therapies, providing ultra-rapid, interactive input on protocols for both clinical trials and single-patient expanded access requests in 3 hours.

Under the leadership of @POTUS @realDonald Trump, @VP, and @SecAzar, @US_FDA recently launched the #Coronavirus Treatment Acceleration Program (#CTAP) https://t.co/eCBVHrUaDV

The donations of these medications are expected to help ease supply pressures for them. We are working with manufacturers to increase production to ensure their availability to patients who need them for treatment of malaria, lupus and rheumatoid arthritis.

An EUA may be issued if FDA determines that, amongvother criteria, the known/potential benefits of the product, when used to diagnose, prevent or treat the identified disease/condition, outweigh the known/potential risks & there are no adequate, approved, available alternatives.

No firms are reporting drug shortages due to #COVID19, including the approximately 20 drug products that are solely sourced from China. https://t.co/aNk4642Ty7

We are reaching out to manufacturers and compiling information about the supply chain at this time, but that report does not accurately reflect our current assessment.

The FDA and industry have to accelerate the adoption of advanced and smart manufacturing technologies to strengthen the nation’s public health infrastructure. To this end, the FDA is creating a new collaboration with @NIST. #FDAVoices https://t.co/mfpGYpWDSt

So far at the IMFs in FY 2020 the FDA has screened and refused admission to more than 34,000 products with more than 24,000 being violative drug products that were destroyed.

As we continue to fight #COVID19, FDA remains steadfast in making real time decisions based on evolving information and science. This has been consistently applied throughout the pandemic in our approach to diagnostics, PPE and potential therapies.

RT @AnandShahFDA: Having fun in the sun? Practice social distancing, wear a mask, and wash your hands. Also check out @US_FDA's lates… https://t.co/oVc60hONiM

If you’ve had #COVID19, please help your family, friends, neighbors, and fellow Americans by donating plasma today QT @WhiteHouse: "We've seen that this is a safe treatment, and we're encouraged by the early, promising data that we've seen ... Th… https://t.co/qZf6btF8oT)

RT @Mike_Pence: Wheels up to Florida with @SteveFDA to visit @umiamimedicine to mark the beginning of Phase-3 clinical trials with… https://t.co/V9sreCjsiu

Submit your questions for our next session of #AskFDA. QT @US_FDA: Let’s do it again! Join @SteveFDA as he answers your questions about anything FDA. Send your questions using… https://t.co/zsaltoO3bK)

RT @DrAbernethyFDA: It was a pleasure to participate in The Next Era of Healthcare @BloombergLive discussion including the new use of t… https://t.co/Dld8mKzpgf

We are proud to participate in the COVID-19 Diagnostics Evidence Accelerator, a multi-stakeholder project organized by @reaganudall in collaboration with @CancerResearch.

RT @US_FDA: Throughout its history, FDA has warned Americans against buying fraudulent medical devices. Be a #cautiousconsumer… https://t.co/m1MQhHRhy0

FDA will continue to enhance & expand its work to accelerate novel #COVID19-related therapies & intends to provide additional information in the near future to give Americans a greater understanding of the full extent of our work in this area.

Convalescent plasma & hyperimmune globulin are blood products made from the blood of recovered #COVID19 patients. Because these products contain antibodies to the disease, they may help sick #coronavirus patients by shortening the length or lessening the severity of the illness.

As part of CTAP’s work, FDA is collaborating with government, industry & academic partners to facilitate the development & use of plasma & blood products for the potential treatment of #COVID19. https://t.co/JAjUEBSy6c

FDA has, among other things redeployed medical & regulatory staff to serve on review teams dedicated to #COVID19 therapies, streamlined processes & operations for developers & scientists to send inquiries & requests, & provided resources to health care providers & researchers.

Through CTAP, FDA is triaging requests from developers & scientists seeking to develop new drug & biologic therapies, providing ultra-rapid, interactive input on protocols for both clinical trials and single-patient expanded access requests in 3 hours.

Under the leadership of @POTUS @realDonald Trump, @VP, and @SecAzar, @US_FDA recently launched the #Coronavirus Treatment Acceleration Program (#CTAP) https://t.co/eCBVHrUaDV

The donations of these medications are expected to help ease supply pressures for them. We are working with manufacturers to increase production to ensure their availability to patients who need them for treatment of malaria, lupus and rheumatoid arthritis.

An EUA may be issued if FDA determines that, amongvother criteria, the known/potential benefits of the product, when used to diagnose, prevent or treat the identified disease/condition, outweigh the known/potential risks & there are no adequate, approved, available alternatives.

No firms are reporting drug shortages due to #COVID19, including the approximately 20 drug products that are solely sourced from China. https://t.co/aNk4642Ty7

We are reaching out to manufacturers and compiling information about the supply chain at this time, but that report does not accurately reflect our current assessment.